MedTrace Logo

BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer

NCT02963688 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 298

Last updated 2016-11-15

No results posted yet for this study

Summary

PURPOSE: To investigate the prevalence and clinical correlation of the germline BRCA 1/2 mutation in Korean patients with high grade(HG) serous and/or endometrioid epithelial ovarian cancer (EOC).

PATIENTS AND METHODS: In a nationwide case-control study on EOC conducted in Korea between 2010 and 2015, 298 Korean women with HG serous and/or endometrioid EOC were tested for gBRCA 1/2 mutation, regardless of the family history. Mutation screening was performed using the Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) and Ion PGM platform according to the manufacturer's instructions. Clinical characteristics including survival outcome was assessed in gBRCAm carriers.

Conditions

  • To Investigate the Prevalence of BRCA 1/2 Mutation Among Ovarian Cancer

Interventions

GENETIC

Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform

BRCA1,2 Germline /Somatic mutation test

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Samsung Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2015-12-31
Completion
2015-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02963688 on ClinicalTrials.gov